Ken Suh
Chief Executive Officer,
Sauvie Inc.
United States
Ken has been engaged in leading the formation and growth of pharmaceutical companies and global brands for over 22 years. Prior to forming Sauvie Inc., Ken was the founder and CEO of Willow Biopharma Inc. where he sourced and led the acquisition of Pancreaze for $135 million and simultaneously led the exit of Willow to Vivus Inc. Ken was appointed as president of Vivus (NASDAQ listed in 2018) post transaction. Ken led the growth of Vivus from ~$45 million to ~$78 million in revenue. Today, Vivus is a subsidiary of Icahn Enterprises L.P. (NASDAQ: IEP) and annual revenues have continued to grow to over $90 million. Additional to the commercial growth, Vivus progressed development of a Phase 1 candidate. Prior to the entrepreneurial journey Ken held roles of increasing responsibility at Novartis Canada during his accelerated career. Highlights of key achievements during Ken’s career at Novartis were a global marketing award, marketing leadership of a brand that achieved the best annual growth compared to all other marketed brands at Novartis Canada, a member of Novartis global commercial operations teams and leading the largest oncology franchise to top five global best annual market share gains.
)
){kind=logo}
)
){kind=logo}
){kind=logo}